Tofacitinib with conventional synthetic disease‐modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient‐reported outcomes from a Phase 3 randomized controlled trial

• Published in: International journal of rheumatic diseases Vol. 21; no. 2; pp. 402 - 414
• Main Authors: Li, Zhanguo, An, Yuan, Su, Houheng, Li, Xiangpei, Xu, Jianhua, Zheng, Yi, Li, Guiye, Kwok, Kenneth, Wang, Lisy, Wu, Qizhe
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01-02-2018; John Wiley and Sons Inc
• Subjects: Chronic illnesses; Data processing; Enzyme inhibitors; Fatigue; HAQ; Health risk assessment; Janus kinase; Original; Pain; Patients; patient‐reported outcomes; Quality of life; Rheumatoid arthritis; tofacitinib; patient-reported outcomes; HAQ; pain; rheumatoid arthritis; tofacitinib
• ISSN: 1756-1841; 1756-185X
• DOI: 10.1111/1756-185X.13244

Aim
Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We assess the effect of tofacitinib + conventional synthetic disease‐modifying anti rheumatic drugs (csDMARDs) on patient‐reported outcomes in Chinese patients with RA and inadequate response to DMARDs.
Methods
This analysis of data from the Phase 3 study ORAL Sync included Chinese patients randomized 4 : 4 : 1 : 1 to receive tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily, placebo→tofacitinib 5 mg twice daily, or placebo→tofacitinib 10 mg twice daily, with csDMARDs. Placebo non‐responders switched to tofacitinib at 3 months; the remaining placebo patients switched at 6 months. Least squares mean changes from baseline were reported for Health Assessment Questionnaire‐Disability Index (HAQ‐DI), patient assessment of arthritis pain (Pain), patient global assessment of disease activity (PtGA), physician global assessment of disease activity (PGA), Functional Assessment of Chronic Illness Therapy‐Fatigue (FACIT‐F) scores, Short Form 36 (SF‐36), and Work Limitations Questionnaire (WLQ), using a mixed‐effects model for repeated measures.
Results
Overall, 216 patients were included (tofacitinib 5 mg twice daily, n = 86; tofacitinib 10 mg twice daily, n = 86; placebo→tofacitinib 5 mg twice daily, n = 22; placebo→tofacitinib 10 mg twice daily, n = 22). At month 3, tofacitinib elicited significant improvements in HAQ‐DI, Pain, PtGA, PGA and SF‐36 Physical Component Summary scores. Improvements were generally maintained through 12 months.
Conclusion
Tofacitinib 5 and 10 mg twice daily + csDMARDs resulted in improvements in health‐related quality of life, physical function and Pain through 12 months in Chinese patients with RA.